François Degorce, Amy Card, Sharon Soh, Eric Trinquet, Glenn P Knapik, Bing Xie
{"title":"HTRF:一种为药物发现量身定制的技术-对理论方面和最近应用的回顾。","authors":"François Degorce, Amy Card, Sharon Soh, Eric Trinquet, Glenn P Knapik, Bing Xie","doi":"10.2174/1875397300903010022","DOIUrl":null,"url":null,"abstract":"<p><p>HTRF (Homogeneous Time Resolved Fluorescence) is the most frequently used generic assay technology to measure analytes in a homogenous format, which is the ideal platform used for drug target studies in high-throughput screening (HTS). This technology combines fluorescence resonance energy transfer technology (FRET) with time-resolved measurement (TR). In TR-FRET assays, a signal is generated through fluorescent resonance energy transfer between a donor and an acceptor molecule when in close proximity to each other. Buffer and media interference is dramatically reduced by dual-wavelength detection, and the final signal is proportional to the extent of product formation. The HTRF assay is usually sensitive and robust that can be miniaturized into the 384 and 1536-well plate formats. This assay technology has been applied to many antibody-based assays including GPCR signaling (cAMP and IP-One), kinases, cytokines and biomarkers, bioprocess (antibody and protein production), as well as the assays for protein-protein, proteinpeptide, and protein-DNA/RNA interactions.Since its introduction to the drug-screening world over ten years ago, researchers have used HTRF to expedite the study of GPCRs, kinases, new biomarkers, protein-protein interactions, and other targets of interest. HTRF has also been utilized as an alternative method for bioprocess monitoring. The first-generation HTRF technology, which uses Europium cryptate as a fluorescence donor to monitor reactions between biomolecules, was extended in 2008 through the introduction of a second-generation donor, Terbium cryptate (Tb), enhancing screening performance. Terbium cryptate possesses different photophysical properties compared to Europium, including increased quantum yield and a higher molar extinction coefficient. In addition to being compatible with the same acceptor fluorophors used with Europium, it can serve as a donor fluorophore to green-emitting fluors because it has multiple emission peaks including one at 490 nm. Moreover, all Terbium HTRF assays can be read on the same HTRF-compatible instruments as Europium HTRF assays.Overall, HTRF is a highly sensitive, robust technology for the detection of molecular interactions in vitro and is widely used for primary and secondary screening phases of drug development. This review addresses the general principles of HTRF and its current applications in drug discovery.</p>","PeriodicalId":88232,"journal":{"name":"Current chemical genomics","volume":"3 ","pages":"22-32"},"PeriodicalIF":0.0000,"publicationDate":"2009-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1875397300903010022","citationCount":"373","resultStr":"{\"title\":\"HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications.\",\"authors\":\"François Degorce, Amy Card, Sharon Soh, Eric Trinquet, Glenn P Knapik, Bing Xie\",\"doi\":\"10.2174/1875397300903010022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>HTRF (Homogeneous Time Resolved Fluorescence) is the most frequently used generic assay technology to measure analytes in a homogenous format, which is the ideal platform used for drug target studies in high-throughput screening (HTS). This technology combines fluorescence resonance energy transfer technology (FRET) with time-resolved measurement (TR). In TR-FRET assays, a signal is generated through fluorescent resonance energy transfer between a donor and an acceptor molecule when in close proximity to each other. Buffer and media interference is dramatically reduced by dual-wavelength detection, and the final signal is proportional to the extent of product formation. The HTRF assay is usually sensitive and robust that can be miniaturized into the 384 and 1536-well plate formats. This assay technology has been applied to many antibody-based assays including GPCR signaling (cAMP and IP-One), kinases, cytokines and biomarkers, bioprocess (antibody and protein production), as well as the assays for protein-protein, proteinpeptide, and protein-DNA/RNA interactions.Since its introduction to the drug-screening world over ten years ago, researchers have used HTRF to expedite the study of GPCRs, kinases, new biomarkers, protein-protein interactions, and other targets of interest. HTRF has also been utilized as an alternative method for bioprocess monitoring. The first-generation HTRF technology, which uses Europium cryptate as a fluorescence donor to monitor reactions between biomolecules, was extended in 2008 through the introduction of a second-generation donor, Terbium cryptate (Tb), enhancing screening performance. Terbium cryptate possesses different photophysical properties compared to Europium, including increased quantum yield and a higher molar extinction coefficient. In addition to being compatible with the same acceptor fluorophors used with Europium, it can serve as a donor fluorophore to green-emitting fluors because it has multiple emission peaks including one at 490 nm. Moreover, all Terbium HTRF assays can be read on the same HTRF-compatible instruments as Europium HTRF assays.Overall, HTRF is a highly sensitive, robust technology for the detection of molecular interactions in vitro and is widely used for primary and secondary screening phases of drug development. This review addresses the general principles of HTRF and its current applications in drug discovery.</p>\",\"PeriodicalId\":88232,\"journal\":{\"name\":\"Current chemical genomics\",\"volume\":\"3 \",\"pages\":\"22-32\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-05-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2174/1875397300903010022\",\"citationCount\":\"373\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current chemical genomics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1875397300903010022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current chemical genomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875397300903010022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 373
摘要
HTRF(均质时间分辨荧光)是最常用的通用分析技术,用于测量均质格式的分析物,这是用于高通量筛选(HTS)中药物靶标研究的理想平台。该技术结合了荧光共振能量转移技术(FRET)和时间分辨测量(TR)。在TR-FRET检测中,当供体分子和受体分子彼此靠近时,通过荧光共振能量转移产生信号。缓冲器和介质干扰通过双波长检测显着减少,最终信号与产品形成的程度成正比。HTRF检测通常是敏感和稳健的,可以小型化到384和1536孔板格式。该检测技术已应用于许多基于抗体的检测,包括GPCR信号(cAMP和IP-One)、激酶、细胞因子和生物标志物、生物过程(抗体和蛋白质生产),以及蛋白质-蛋白质、蛋白肽和蛋白质- dna /RNA相互作用的检测。自十多年前htf被引入药物筛选领域以来,研究人员已经使用htf加速了对gpcr、激酶、新的生物标志物、蛋白质-蛋白质相互作用和其他感兴趣靶点的研究。htf也被用作生物过程监测的一种替代方法。第一代HTRF技术使用隐态铕作为荧光供体来监测生物分子之间的反应。2008年,通过引入第二代隐态铽(Tb), HTRF技术得到了扩展,从而增强了筛选性能。与铕相比,隐态铽具有不同的光物理性质,包括更高的量子产率和更高的摩尔消光系数。除了与与铕相同的受体荧光团兼容外,它还可以作为绿色荧光的供体荧光团,因为它具有多个发射峰,包括一个在490 nm处的发射峰。此外,所有铽HTRF分析都可以在与铕HTRF分析相同的HTRF兼容的仪器上读取。总之,HTRF是一种高度敏感、可靠的体外分子相互作用检测技术,广泛用于药物开发的初级和二级筛选阶段。本文综述了HTRF的一般原理及其在药物发现中的应用。
HTRF: A technology tailored for drug discovery - a review of theoretical aspects and recent applications.
HTRF (Homogeneous Time Resolved Fluorescence) is the most frequently used generic assay technology to measure analytes in a homogenous format, which is the ideal platform used for drug target studies in high-throughput screening (HTS). This technology combines fluorescence resonance energy transfer technology (FRET) with time-resolved measurement (TR). In TR-FRET assays, a signal is generated through fluorescent resonance energy transfer between a donor and an acceptor molecule when in close proximity to each other. Buffer and media interference is dramatically reduced by dual-wavelength detection, and the final signal is proportional to the extent of product formation. The HTRF assay is usually sensitive and robust that can be miniaturized into the 384 and 1536-well plate formats. This assay technology has been applied to many antibody-based assays including GPCR signaling (cAMP and IP-One), kinases, cytokines and biomarkers, bioprocess (antibody and protein production), as well as the assays for protein-protein, proteinpeptide, and protein-DNA/RNA interactions.Since its introduction to the drug-screening world over ten years ago, researchers have used HTRF to expedite the study of GPCRs, kinases, new biomarkers, protein-protein interactions, and other targets of interest. HTRF has also been utilized as an alternative method for bioprocess monitoring. The first-generation HTRF technology, which uses Europium cryptate as a fluorescence donor to monitor reactions between biomolecules, was extended in 2008 through the introduction of a second-generation donor, Terbium cryptate (Tb), enhancing screening performance. Terbium cryptate possesses different photophysical properties compared to Europium, including increased quantum yield and a higher molar extinction coefficient. In addition to being compatible with the same acceptor fluorophors used with Europium, it can serve as a donor fluorophore to green-emitting fluors because it has multiple emission peaks including one at 490 nm. Moreover, all Terbium HTRF assays can be read on the same HTRF-compatible instruments as Europium HTRF assays.Overall, HTRF is a highly sensitive, robust technology for the detection of molecular interactions in vitro and is widely used for primary and secondary screening phases of drug development. This review addresses the general principles of HTRF and its current applications in drug discovery.